Martin Maron to Fibrosis
This is a "connection" page, showing publications Martin Maron has written about Fibrosis.
Connection Strength
1.135
-
Rowin EJ, Maron BJ, Maron MS. The Hypertrophic Cardiomyopathy Phenotype Viewed Through the Prism?of?Multimodality Imaging: Clinical and Etiologic Implications. JACC Cardiovasc Imaging. 2020 09; 13(9):2002-2016.
Score: 0.163
-
Maron MS, Chan RH, Kapur NK, Jaffe IZ, McGraw AP, Kerur R, Maron BJ, Udelson JE. Effect of Spironolactone on Myocardial Fibrosis and Other Clinical Variables in Patients with Hypertrophic Cardiomyopathy. Am J Med. 2018 07; 131(7):837-841.
Score: 0.145
-
Maron BJ, Maron MS. LGE Means Better Selection of HCM?Patients for Primary Prevention Implantable Defibrillators. JACC Cardiovasc Imaging. 2016 12; 9(12):1403-1406.
Score: 0.129
-
Maron MS. Clinical utility of cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Cardiovasc Magn Reson. 2012 Feb 01; 14:13.
Score: 0.094
-
Maron MS. The current and emerging role of cardiovascular magnetic resonance imaging in hypertrophic cardiomyopathy. J Cardiovasc Transl Res. 2009 Dec; 2(4):415-25.
Score: 0.081
-
Kelley-Hedgepeth A, Maron MS. Imaging techniques in the evaluation and management of hypertrophic cardiomyopathy. Curr Heart Fail Rep. 2009 Sep; 6(3):135-41.
Score: 0.080
-
Maron MS, Maron BJ, Harrigan C, Buros J, Gibson CM, Olivotto I, Biller L, Lesser JR, Udelson JE, Manning WJ, Appelbaum E. Hypertrophic cardiomyopathy phenotype revisited after 50 years with cardiovascular magnetic resonance. J Am Coll Cardiol. 2009 Jul 14; 54(3):220-8.
Score: 0.079
-
Kelley-Hedgepeth A, Towbin JA, Maron MS. Images in cardiovascular medicine. Overlapping phenotypes: left ventricular noncompaction and hypertrophic cardiomyopathy. Circulation. 2009 Jun 16; 119(23):e588-9.
Score: 0.079
-
Adabag AS, Maron BJ, Appelbaum E, Harrigan CJ, Buros JL, Gibson CM, Lesser JR, Hanna CA, Udelson JE, Manning WJ, Maron MS. Occurrence and frequency of arrhythmias in hypertrophic cardiomyopathy in relation to delayed enhancement on cardiovascular magnetic resonance. J Am Coll Cardiol. 2008 Apr 08; 51(14):1369-74.
Score: 0.072
-
Massera D, Sherrid MV, Maron MS, Rowin EJ, Maron BJ. How common is hypertrophic cardiomyopathy? really?: Disease prevalence revisited 27?years after CARDIA. Int J Cardiol. 2023 07 01; 382:64-67.
Score: 0.051
-
Maron BA, Wang RS, Shevtsov S, Drakos SG, Arons E, Wever-Pinzon O, Huggins GS, Samokhin AO, Oldham WM, Aguib Y, Yacoub MH, Rowin EJ, Maron BJ, Maron MS, Loscalzo J. Individualized interactomes for network-based precision medicine in hypertrophic cardiomyopathy with implications for other clinical pathophenotypes. Nat Commun. 2021 02 08; 12(1):873.
Score: 0.044
-
Habib M, Adler A, Fardfini K, Hoss S, Hanneman K, Rowin EJ, Maron MS, Maron BJ, Rakowski H, Chan RH. Progression of Myocardial Fibrosis in Hypertrophic Cardiomyopathy: A Cardiac Magnetic Resonance Study. JACC Cardiovasc Imaging. 2021 05; 14(5):947-958.
Score: 0.043
-
Urbano-Moral JA, Rowin EJ, Maron MS, Crean A, Pandian NG. Investigation of global and regional myocardial mechanics with 3-dimensional speckle tracking echocardiography and relations to hypertrophy and fibrosis in hypertrophic cardiomyopathy. Circ Cardiovasc Imaging. 2014 Jan; 7(1):11-9.
Score: 0.027
-
Spoladore R, Maron MS, D'Amato R, Camici PG, Olivotto I. Pharmacological treatment options for hypertrophic cardiomyopathy: high time for evidence. Eur Heart J. 2012 Jul; 33(14):1724-33.
Score: 0.024
-
Rowin EJ, Maron MS, Lesser JR, Maron BJ. CMR with late gadolinium enhancement in genotype positive-phenotype negative hypertrophic cardiomyopathy. JACC Cardiovasc Imaging. 2012 Jan; 5(1):119-22.
Score: 0.023